Office of National Drug Control Policy


The Office of National Drug Control Policy is a component of the Executive Office of the President of the United States.
The director of the ONDCP, colloquially known as the drug czar, heads the office. "Drug czar" was a term first used in the media by President Richard Nixon in 1971. In addition to running the ONDCP, the director evaluates, coordinates, and oversees both the international and domestic anti-drug efforts of executive branch agencies and ensures that such efforts sustain and complement state and local anti-drug activities. The director advises the president regarding changes in the organization, management, budgeting, and personnel of federal agencies that affect U.S. anti-drug efforts; and regarding federal agency compliance with their obligations under the National Drug Control Strategy, an annual report required by law. Prior to Rahul Gupta taking office in November, 2021, the most recent director was James. W. Carroll, who took over from former director Michael Botticelli. The fiscal year 2011 National Drug Control Budget proposed by the Obama administration devoted significant new resources to the prevention and treatment of drug abuse. These resources were complemented by an aggressive effort to enhance domestic law enforcement, interdiction, and supply control programs. New resources, valued at $340 million, were added to the prevention and treatment of drug use.

Programs

The programs directed by the ONDCP include:

Bipartisan support for drug czar

The Anti-Drug Abuse Act of 1988, which created the Office of National Drug Control Policy, was the product of bi-partisan support. It was co-sponsored in the House of Representatives by Democratic and Republican leaders, Tom Foley and Robert Michel, and it passed by margins of 346–11 and 87–3 in the House and Senate, respectively. Upon signing the law, Ronald Reagan said, "This bill is the product of a bipartisan effort."

1993 downsize

In February 1993, new U.S. president Bill Clinton greatly downsized the Office of National Drug Control Policy by 84 percent, reducing the staff size from 146 to 25.

Funding

In September 2002, the Senate Appropriations Committee recommended that salaries and expenses at ONDCP be reduced from $26.6 million in fiscal 2006 to $11.5 million in fiscal 2007, to "more closely reflect actual performance." Committee members said they would request funding for a study of ONDCP by the National Academy of Public Administration. They also ordered a Government Accountability Office study on the distribution of grants. Plus, they directed the Director to provide quarterly updates on travel expenditures, staffing levels and plans for future hirings.
In 2011, the ONDCP requested funding for 98 full-time employees, 64 of whom would be paid at either GS-15, GS-14, or SES pay grades, or more than $105,211.00 yearly, being adjusted for Washington, D.C. cost of living expenses.

High-Intensity Drug Trafficking Program

In 2005, the Bush administration proposed transferring the $225 million High-Intensity Drug Trafficking Program from ONDCP to the Department of Justice. The program gives additional money to designated areas with chronic illicit drug problems. According to The Washington Post, "Many lawmakers oppose the transfer for fear the program would become less of a priority."

Anti-legalization Policy

By law, the drug czar must oppose any attempt to legalize the use of illicit drugs. According to the "Office of National Drug Control Policy Reauthorization Act of 1998" the director of the ONDCP
shall ensure that no Federal funds appropriated to the Office of National Drug Control Policy shall be expended for any study or contract relating to the legalization of a substance listed in schedule I of section 202 of the Controlled Substances Act and take such actions as necessary to oppose any attempt to legalize the use of a substance that –
1. is listed in schedule I of section 202 of the Controlled Substances Act ; and
2. has not been approved for use for medical purposes by the Food and Drug Administration;

The Government Accountability Office has found that this law authorizes the ONDCP to disseminate information in order to oppose legalization:
Finally, apart from considerations of whether any particular law has been violated, you have asked whether the Deputy Director's letter disseminated misleading information in connection with statements relating to the debate over legalization of marijuana. Clearly, the Deputy Director's statements reflect one perspective regarding marijuana – a perspective that is disputed by others with different viewpoints. However, ONDCP is specifically charged with the responsibility for "taking such actions as necessary to oppose any attempt to legalize the use" of certain controlled substances such as marijuana – a responsibility which logically could include the making of advocacy statements in opposition to legalization efforts. The Deputy Director's statements about marijuana are thus within the statutory role assigned to ONDCP. Given this role, we do not see a need to examine the accuracy of the Deputy Director's individual statements in detail.

Effectiveness of ONDCP

Extent of drug use in the U.S.

In September 2006, the office reported that the 2005 survey of 67,500 people found that 8.1 percent reported using an illicit drug in the 30 days prior to being asked about their drug use, which equates to 19.7 million people nationwide. The percentage was up slightly compared to 2004, although youth drug use declined for the third year in a row. While the ONDCP measures their efficacy against prior use statistics within the U.S., they do not publicize how these statistics compare against other countries at the time in their communications to the press. In 2008, ONDCP reported that actual youth drug use, as measured as the percent reporting past month use, declined from 19.4% to 14.8% among middle and high school students between 2001 and 2007.

Anti-marijuana advertising

In August 2001, the office told a Congressional committee that its National Youth Anti-Drug Media Campaign "has been the most visible symbol of the federal government's commitment to drug prevention," and that the office was "investing $7 million a year in performance measurement to determine the effectiveness" of the campaign. The statement also said "We believe there is a strong body of evidence that indicates the campaign is working, as planned, to change drug attitudes, intentions and use."
In 2002, according to a multiyear study by the research firm hired by the office, teenagers exposed to federal anti-drug ads were no less likely to use drugs for having viewed them, and some young girls said they were even more likely to give drugs a try. Walters blamed poor ads that weren't resonating with teenagers. Walters promised in Senate testimony in 2002 that he would show results within a year or admit failure, and Congress agreed to extend the campaign through 2003 while cutting funding for the ads from $170 million in 2002 to $150 million in 2003. An entirely new advertising campaign was created.
In February 2005, a research company hired by the office and the National Institute on Drug Abuse reported that the government's ad campaign aimed at dissuading teens from using marijuana, a campaign that cost $1.4 billion between 1998 and 2006, did not work: "greater exposure to the campaign was associated with weaker anti-drug norms and increases in the perceptions that others use marijuana." The research company was paid $42.7 million for the five-year study. After the February 2005 report was received, the office continued the ad campaign, spending $220 million on the anti-marijuana ads in fiscal years 2005 and 2006.

Other

According to the University of Michigan's annual Monitoring the Future report, the number of young people using drugs in the U.S. declined by 7 percent between 2001 and 2006, though there is no evidence to suggest that government anti-drug programs that were started at the turn of the millennium helped cause this drop.
While cocaine production in Colombia initially decreased with the onset of Plan Colombia, the United Nations declared that in 2005, despite record levels of eradication by the U.S., coca production increased to about.

Controversies

Paying for anti-drug messages in television shows

In the spring of 1998, the ONDCP began offering additional advertising dollars to networks that embedded anti-drug messages in their programming. They developed an accounting system to decide which network shows would be valued and for how much. Receiving advance copies of scripts, they assigned financial value to each show's anti-drug message. Then they would suggest ways that the networks could increase the payments they would get. The WB network's senior vice president for broadcast standards Rick Mater admitted, "The White House did view scripts. They did sign off on them – they read scripts, yes."
Running the campaign for the ONDCP was Alan Levitt, who estimated that between 1998 and 2000 the networks received nearly $25 million in benefits.
One example was with Warner Brothers' show, Smart Guy. The original script portrayed two young people using drugs at a party. Originally depicted as cool and popular, after input from the drug office, "We showed that they were losers and put them in a utility room. That was not in the original script."
Other shows including ER, Beverly Hills, 90210, Chicago Hope, The Drew Carey Show and 7th Heaven also put anti-drug messages into their stories.
In 2000, the Federal Communications Commission, in response to a complaint by the National Organization for the Reform of Marijuana Laws, sent inquiries to five major television networks about these practices. The House Committee on Government Reform's Subcommittee on Criminal Justice, Drug Policy and Human Resources held hearings on the matter on July 11, 2000. In December of that year, the FCC ruled that the networks should have identified the Office of National Drug Control Policy as the sponsor of the television programs.